Among the epiboly-interrupting drugs, several drugs have already been reported to inhibit metastasis-related molecular mechanisms: adrenosterone or zardaverine, which target HSD11β1 or PDE3 and -4, respectively, are reported to inhibit EMT (Nakayama et al., 2020; Kolosionek et al., 2009); racecadotril, which targets enkephalinase, is reported to confer metastatic potential on colon cancer cell (Sasaki et al., 2014); and disulfiram, which targets ALDH (aldehyde dehydrogenase), is reported to confer stem-like properties on metastatic cancer cells (Liu et al., 2013). Here, HSD11B1 is linked to cancer.